Moneycontrol PRO
HomeNewsBusinessCompaniesLupin launches generic hypertension drug in US

Lupin launches generic hypertension drug in US

The US arm of the company, Lupin Pharmaceuticals Inc, has launched Amlodipine and Valsartan tablets in various strengths in the US market after getting final approval from the United States Food and Drug Administration (USFDA), Lupin said in a statement.

April 01, 2015 / 16:14 IST
     
     
    26 Aug, 2025 12:21
    Volume
    Todays L/H
    More

    Drugmaker Lupin has launched its Amlodipine and Valsartan tablets, used for treatment of hypertension, in the US market after getting approval from the American health regulator.

    The US arm of the company, Lupin Pharmaceuticals Inc, has launched Amlodipine and Valsartan tablets in various strengths in the US market after getting final approval from the United States Food and Drug Administration (USFDA), Lupin said in a statement.

    Lupin's Amlodipine and Valsartan tablets are indicated for the treatment of hypertension and to lower blood pressure and is the generic version of Novarts Pharmaceuticals Corporation's Exforge tablets. 

    As per IMS MAT sales data, Exforge tablets had US sales of USD 414.9 million. With this approval, the Mumbai-based firm has received six abbreviated new drug approvals (ANDAs) in the last three months. Lupin shares were trading at Rs 2,033 a piece on the BSE, up 1.29 percent from its previous close. 

    first published: Apr 1, 2015 04:14 pm

    Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

    Subscribe to Tech Newsletters

    • On Saturdays

      Find the best of Al News in one place, specially curated for you every weekend.

    • Daily-Weekdays

      Stay on top of the latest tech trends and biggest startup news.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347